Thursday 15 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • US state Rx plan not legal, says court

US state Rx plan not legal, says court

31 May 2001

The AWARDS (A Washington Alliance to Reduce prescription-DrugSpending) drug discount plan introduced by Washington state Governor Gary Locke has been struck down by a Superior Court Judge, who ruled that the state does not have the authority to implement the program, reports Reuters.

Judge Richard Strophy said Gov Locke's prescription drug buyers club, which covers about 5,000 state residents aged 55 and over without prescription drug coverage, has a laudable goal, but it is not legal.

Individuals pay $15 and families $25 for annual membership of AWARDS, which uses the pharmacy benefit manager and network of pharmacies run by the state employees' preferred provider organization to obtain discounts averaging 20%-25% on medications purchased through pharmacies, and bigger reductions on mail-order purchases. However, the Court ruled that the state Health Care Authority was not empowered to extend its contract with the PBM, Merck-Medco, to include the AWARDS program.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Phesi urges smarter use of oncology trial data as ASCO 2025 nears
Pharmaceutical
Phesi urges smarter use of oncology trial data as ASCO 2025 nears
15 May 2025
Pharmaceutical
Plenty of promise in Pfizer’s ASCO offering
14 May 2025
Pharmaceutical
Latest Trump executive order threatens broad cut to US drug prices
14 May 2025
Biotechnology
Billions to play for in AbbVie and ADARx siRNA tie-up
14 May 2025
Pharmaceutical
Septerna and Novo Nordisk to collaborate on oral obesity and other cardiometabolic diseases
14 May 2025
Pharmaceutical
Tvardi maps out path to Phase II data after Cara merger
14 May 2025
Pharmaceutical
Aficamten scores in Phase III trial, after FDA decision delay
14 May 2025

Company Spotlight

Compugen is a genomics-based drug and diagnostic discovery company.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze